Tirzepatide (Research Use Only)
Chemical Name: Tirzepatide
CAS Number:
2023788-19-2
Molecular Formula:
C225H348N48O68
Molecular Weight: 4810.52–4813.5 g/mol
Sequence:
Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{C20 diacid-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
(reference)
Appearance: White to off-white powder
Storage: −20°C (long-term)
Form: Lyophilized solid; soluble in DMSO
Description
Tirzepatide is a 39-amino acid synthetic polypeptide and dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is widely researched for glycemic control and significant weight-loss effects in metabolic and obesity models. It utilizes albumin affinity modifications (C20 fatty diacid sidechain) for extended half-life and once-weekly use in studies.
(Wikipedia)
(DrugBank)
Research Applications
- Studies on glycemic regulation in metabolic disease and T2DM models
- Obesity research: Significant dose-dependent weight reduction (clinical and preclinical)
- Investigated effects on fasting insulin, HbA1c, cardiovascular risk factors
- Used in high-impact trials for diabetes and obesity
Key Research & Reports
- StatPearls/NCBI Bookshelf (2024): Tirzepatide review and clinical data
- JAMA (2024): Maintenance of Weight Reduction with Tirzepatide
- PMC (2025): Health-related quality of life outcomes in SURMOUNT-2
- PMC (2023): Systematic review on weight loss efficacy and safety
- InVivoChem: Research Grade Tirzepatide
- PubChem Compound Database
- DrugBank Profile – Tirzepatide
Mechanism of Action
Tirzepatide binds to both GIP and GLP-1 receptors, stimulating insulin secretion, inhibiting glucagon, and slowing gastric emptying. This dual incretin agonism leads to improved glucose control and substantial weight loss in research models—distinct from single-incretin peptides.
(DrugBank)
Safety and Handling
Tirzepatide demonstrates strong safety in controlled laboratory research. Store lyophilized powder at −20°C; reconstitute prior to in vitro or in vivo studies. Known mild effects include gastrointestinal symptoms and transient injection reactions in model organisms.
Disclaimer
For laboratory research use only. Not for human consumption, medical, veterinary, or diagnostic use. All data provided is for educational and research purposes.
